World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
78226
World Ranking
7776
National Ranking
297

Overview

Malcolm J. Moore is affiliated with the Princess Margaret Cancer Centre in Canada. Their research primarily spans the fields of medicine and biochemistry, genetics, and molecular biology, with a strong focus on oncology and cancer-related studies.

Their work encompasses several subfields including oncology, cancer research, economics and econometrics, surgery, and pulmonary and respiratory medicine. The specific research topics covered in their publications include pancreatic and hepatic oncology, cancer genomics and diagnostics, colorectal cancer treatments and studies, economic and financial impacts of cancer, health systems and economic evaluations related to quality of life, genetic factors in colorectal cancer, and advances in neuroendocrine tumor research.

The scientist has contributed to multiple papers, with notable recent publications including:

  • Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (2023, Journal of Clinical Oncology)
  • Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial (2023, Journal of Clinical Oncology)
  • Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial (2022, Journal of Clinical Oncology)
  • Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial (2023, JCO Oncology Practice)
  • Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study (2023, Journal of Clinical Oncology)

Their frequent coauthors include Jennifer J. Knox, Robert C. Grant, Steven Gallinger, Anna Dodd, and Grainne M. O'Kane. These collaborations point to a network engaged in clinical oncology and cancer therapeutic research.

Malcolm J. Moore's research has been published predominantly in the following venues:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • World Journal of Gastroenterology
  • Cancer Medicine

Best Publications

  • Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

    H A Burris;M J Moore;J Andersen;M R Green

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;David Goldstein;John Hamm;Arie Figer

  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

    Christos S Karapetis;Shirin Khambata-Ford;Derek J Jonker;Chris J O'Callaghan

  • Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

    Leonard B. Saltz;John V. Cox;Charles Blanke;Lee S. Rosen

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

    Christine M. Ribic;Daniel J. Sargent;Malcolm J. Moore;Malcolm J. Moore;Stephen N. Thibodeau

  • Cetuximab for the Treatment of Colorectal Cancer

    Derek J Jonker;Chris J O'Callaghan;Christos S Karapetis;John R Zalcberg

  • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

    I. F. Tannock;D. Osoba;M. R. Stockler;D. S. Ernst

  • Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Monika Krzyzanowska;Breffni Hannon;Breffni Hannon

  • Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

    Hans von der Maase;Lisa Sengelov;James T. Roberts;Sergio Ricci

  • Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

    Daniel J. Sargent;Silvia Marsoni;Genevieve Monges;Stephen N. Thibodeau

  • Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

    John P. Neoptolemos;Deborah D. Stocken;Claudio Bassi;Paula Ghaneh

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Advanced pancreatic carcinoma: current treatment and future challenges.

    Anastasios Stathis;Malcolm J. Moore

  • Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

    Eric Van Cutsem;Walter L. Vervenne;Jaafar Bennouna;Yves Humblet

  • A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

    M. L. Rothenberg;M. J. Moore;M. C. Cripps;J. S. Andersen

  • Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

    Emmanuel Mitry;Anthony L.A. Fields;Harry Bleiberg;Roberto Labianca

  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero

  • Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer

    H. von der Maase;L. Sengelov;J.T. Roberts;S. Ricci

Frequent Co-Authors

Lillian L. Siu
Lillian L. Siu University of Toronto
David W. Hedley
David W. Hedley Princess Margaret Cancer Centre
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Padraig Warde
Padraig Warde Princess Margaret Cancer Centre
Dongsheng Tu
Dongsheng Tu Queen's University
Michael A.S. Jewett
Michael A.S. Jewett University of Toronto
Gary Rodin
Gary Rodin Princess Margaret Cancer Centre
John R. Zalcberg
John R. Zalcberg Monash University
Steven Gallinger
Steven Gallinger Ontario Institute for Cancer Research
Camilla Zimmermann
Camilla Zimmermann University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to a variety of related healthcare degrees and career pathways you can pursue online. For registered nurses aiming to advance their careers, the adn to fnp pathway allows experienced RNs with an associate degree to work toward becoming a Family Nurse Practitioner through flexible bridge programs.

If your interests include preventative health or wellness, an online nutrition degree can help you build expertise in dietetics and health education—a growing area in medicine that offers diverse job opportunities.

For those who wish to step into healthcare administration, consider enrolling in one of the best mha programs. These CAHME-accredited online Master of Health Administration programs prepare graduates for leadership roles in hospitals, clinics, or public health sectors.

Additionally, working nurses may be interested in an rn to bsn online without clinicals program, which offers a convenient way to further nursing education without needing on-site clinical training. Each of these options provides flexible, reputable ways to advance in today’s healthcare landscape.

Best Scientists Citing Malcolm J. Moore

Trending Scientists